Table 1 Baseline characteristics
Characteristic | Total (n = 100) | Isavuconazole (n = 33) | Voriconazole (n = 34) | Posaconazole (n = 33) | P-value |
|---|---|---|---|---|---|
Age, years | 55.9 ± 13.7 | 58.8 ± 14.0 | 56.9 ± 11.4 | 52.1 ± 15.1 | 0.124 |
Female, n (%) | 46 (46) | 16 (48.5) | 14 (41.2) | 16 (48.5) | 0.785 |
Baseline Dialysis, n (%) | 7 (7) | 3 (9.1) | 2 (5.9) | 2 (6.1) | 0.852 |
Baseline Serum Creatinine, mg/dL | 1.23 ± 0.82 | 1.57 ± 1.09 | 0.88 ± 0.42 | 1.24 ± 0.66 | 0.002 |
Primary diagnosis of Oncology, n (%) | 62 (62) | 17 (51.5) | 23 (67.6) | 22 (66.7) | 0.097 |
Hematologic Malignancy, n (%) | 58 (93.6) | 16 (94.1) | 22 (95.6) | 20 (90.9) | 0.806 |
Primary diagnosis of Solid Organ Transplant, n (%) | 26 (26) | 14 (42.4) | 5 (14.7) | 7 (21.2) | 0.097 |
Baseline AST, units/L | 27.3 ± 36.0 | 22.0 ± 17.7 | 21.9 ± 15.5 | 36.4 ± 41.8 | 0.053 |
Baseline ALT, units/L | 26.8 ± 28.2 | 22.2 ± 22.0 | 22.5 ± 22.1 | 37.1 ± 53.3 | 0.160 |
Baseline QTc, milliseconds | 457 ± 40 | 478 ± 46 | 445 ± 29 | 450 ± 35 | 0.001 |
Concurrent echinocandin therapy, n (%) | 23 (23) | 8 (24.2) | 5 (14.7) | 10 (30.3) | 0.298 |
Concurrent QTc prolonging medications, n (%) | 83 (83) | 24 (72.7) | 28 (82.35) | 31 (93.9) | 0.057 |
Concurrent Immunosuppression, n (%) | 52 (52) | 20 (60.6) | 17 (50.0) | 15 (45.4) | 0.447 |
Formal infectious disease team consultation, n (%) | 71 (71) | 28 (84.8) | 20 (58.8) | 23 (69.7) | 0.055 |
Indication for use | |||||
Primary, n (%) | 58 (58) | 10 (30.3) | 28 (82.4) | 20 (60.6) | < 0.001 |
Refractory, n (%) | 24 (24) | 13 (39.4) | 4 (11.8) | 7 (21.2) | 0.027 |
Intolerance, n (%) | 16 (16) | 9 (27.3) | 1 (2.9) | 6 (18.2) | 0.011 |
Other, n (%) | 2 (2) | 1 (3.0) | 1 (2.9) | 0 (0) | 0.444 |
Treatment diagnosis | |||||
Zygomycosis, n (%) | 8 (8.33) | 3 (9.1) | 0 (0.0) | 5 (15.2) | 0.101 |
Aspergillosis, n (%) | 30 (31.2) | 12 (36.4) | 10 (33.3) | 8 (24.2) | |
Empiric treatment, n (%) | 58 (60.4) | 18 (54.6) | 20 (66.7) | 20 (60.6) | |